Massachusetts General Hospital, Boston, MA 02114, USA.
Future Oncol. 2010 Mar;6(3):391-405. doi: 10.2217/fon.09.172.
According to the 2008 American Cancer Society statistics, cancer remains the second leading cause of death in American today. Early detection, innovative surgery, new drugs and increased public education regarding avoidable risk factors, such as smoking, have had significant impact on the incidence and survival rates of many cancers, while overall death rates from all cancers have declined a modest 5% over the past 50 years. Ovarian cancer statistics, however, have not been as encouraging. Despite recent advances in the management of this disease, 5-year survival has not improved, and the search continues for rationally designed new treatments. Müllerian Inhibiting Substance is a strong candidate because it addresses many of the deficiencies of existing treatments. Namely, Müllerian Inhibiting Substance has little demonstrated toxicity, it complements the activity of known anticancer drugs, it is highly specific against cancers expressing its receptor and it inhibits the proliferation of drug-resistant tumors.
根据 2008 年美国癌症协会的统计数据，癌症仍然是当今美国的第二大死因。早期发现、创新手术、新药以及针对可避免的风险因素（如吸烟）的公众教育的增加，对许多癌症的发病率和存活率产生了重大影响，而过去 50 年来，所有癌症的总体死亡率仅下降了 5%。然而，卵巢癌的统计数据并不那么令人鼓舞。尽管最近在这种疾病的治疗方面取得了进展，但 5 年生存率并没有提高，人们仍在继续寻找合理设计的新治疗方法。Müllerian Inhibiting Substance 是一个强有力的候选者，因为它解决了现有治疗方法的许多缺陷。具体来说，Müllerian Inhibiting Substance 的毒性较小，它可以补充已知抗癌药物的活性，对表达其受体的癌症具有高度特异性，并抑制耐药肿瘤的增殖。
